AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00959062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Preparation visually identical to clonidine.
Study NCT03271476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR psychotherapy
Description: Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient supporting Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care Visit 8 : EMDR psychotherapy care ans questionnaires Visit 9 (one month after) : semi-directive interview and data recovery (questionnaires)
Study NCT03324984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% chloroprocaine
Description: In 2018, 1% Chloroprocaine was approved by the FDA for spinal anesthesia use.
Study NCT03324984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.75% bupivacaine
Description: Bupivacaine is used on label
Study NCT02710786 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric bypass
Description: Gastric bypass surgery, i.e., small gastric pouch and excluded main stomach
Study NCT00003511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Multiple Myeloma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT02731664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: Intravenous infusion of GLP-1
Study NCT02731664 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous saline
Description: Control
Study NCT02347514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes group visit
Study NCT05177406 — intervention group
Intervention type: OTHER
Intervention: Aimovig
Description: patients newly initiating Aimovig therapy
Study NCT00076791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 900 mg of TDF combined with 600 mg emtricitabine
Study NCT00076791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Description: 600 mg oral dose of TDF
Study NCT03975556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally tailored food and diet advice
Description: Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
Study NCT03975556 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard healthy eating advice
Description: Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate dietary recommendations
Study NCT02574000 — intervention group
Intervention type: OTHER
Intervention: ShoulderQ which is a shoulder pain questionnaire
Description: Questions regarding shoulder pain at rest, during movement and at night with visual analogue scales. Factors affecting shoulder pain.
Study NCT02574000 — intervention group
Intervention type: OTHER
Intervention: Clinical shoulder examination
Description: Shoulder-Hand-Score (measuring pain, oedema, passive range of movement), muscle strength (using Oxford scale and National Institute of Health Stroke Scale (NIHSS) upper limbe motor and shoulder joint palpation (recording subluxation and soft-tissue pain).
Study NCT05494827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular consumption of natural mineral water Borjomi® with high bicarbonate content
Description: Natural mineral water Borjomi® is a transparent mineral water with specific alkaline taste and smell. The chemical composition includes sodium hydrocarbonate (HCO2-) 3995 mg/l (3500-5000 mg/l), chlorides (Cl-) 360 mg/l (250-500 mg/l), and nitrites (NO2-) \<0.005 mg/l (up to 1 mg/l). The Borjomi water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. The day before testing, participants were asked to abstain from their routine training and other physical activities.
Study NCT05494827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular consumption of processed drinking water Smart Spring®
Description: Processed drinking water Smart Spring® has no colour and smell with delicate specific taste. The chemical composition includes sodium (Na+) 33.6 mg/l, magnesium (Mg2+) 10.03 mg/l, calcium (Ca2+) 34.57 mg/l, chlorides (Cl-) 69.79 mg/l, sulfates (SO42-) 22.00 mg/l, and hydrocarbonates (HCO2-) 96.48 mg/l. The Smart Spring® water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. The day before testing, participants were asked to abstain from their routine training and other physical activities.
Study NCT05494827 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular consumption of still drinking water
Description: Still drinking water Святой Источник®is a standard steal drinking water, that has no colour, taste, and smell. The Святой Источник® water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. Participants were asked to abstain from mineral water consumption for the entire observation period.
Study NCT01342822 — intervention group
Intervention type: DEVICE
Intervention: Angioplasty (PROMUS Element™, and Xience™ Prime stent)
Description: Patients with symptomatic ischemic heart disease due to stenotic lesions amenable to percutaneous treatment with a drug eluting stent in a consecutive unselected patient population, provided that the proposed research use of the product is consistent with the approved (labeled) uses of such product and with the reimbursed indications (in countries where reimbursement procedure applies, eg France) and does not violate any other applicable law, regulation or ethical directive/code.
Study NCT03809806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pelvic Organ Prolapse Quantification (POPQ) staging
Description: Pelvic Organ Prolapse staging before and 1 year after the procedure
Study NCT02671201 — intervention group
Intervention type: OTHER
Intervention: Education
Description: Different methods in education of emergency ultrasound
Study NCT03809806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Postoperative questionnaire
Description: Postoperative questionnaire assessing quality of life fulfilled by patients 1 year after procedure
Study NCT03809806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: The Short Form Health Survey (SF 36) questionnaire
Description: patients fulfilled questionnaire before and 1 year after procedure
Study NCT00760695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dronabinol
Description: tablets, twice daily, for 4 weeks
Study NCT00760695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets, twice daily, for 4 weeks
Study NCT00031681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine
Description: Given IV
Study NCT00031681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00031681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies
Study NCT03957603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition Suspension (TFP-DM)
Description: Individualized dietary and lifestyle intervention combined with the recommendation of Enteral Nutrition Suspension (TPF-DM, Diason 0.75 kcal/ml)
Study NCT03957603 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Nutrition Therpay
Description: Individualized dietary and lifestyle intervention
Study NCT06049966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: TECENTRIQ C/S.SOL.IN 1200MG/VIAL (20ML) 1 VIAL x 20ML
Study NCT06049966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: SOL.INF 450MG/45ML VIAL ΒΤx1VIALx45ML
Study NCT06049966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: SOL.INF 450MG/45ML VIAL ΒΤx1VIALx45ML
Study NCT06049966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: ETOPOSIDE/PHARMACHEMIE SOL.INF 100MG/5ML VIAL BT x 10 VIALS x 5 ML
Study NCT06049966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: ETOPOSIDE/PHARMACHEMIE SOL.INF 100MG/5ML VIAL BT x 10 VIALS x 5 ML
Study NCT03003039 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB241
Description: Single intravenous infusion (IV) 375 mg/m2
Study NCT03003039 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Single intravenous infusion (IV) 375 mg/m2
Study NCT03386396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein/low carbohydrate
Description: A high protein/low carbohydrate shake will be given to the child.
Study NCT03386396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High carbohydrate/low protein
Description: A high carbohydrate/low protein shake will be given to the child
Study NCT01246869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]fluoro-2-deoxy-D-glucose (FDG)
Description: Brain scan with imaging tracer used for measuring glucose metabolism in the assessment, diagnosis, and staging of patients with cancer
Study NCT01246869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1H-1-(3-[18F]-fluoro-2-hydroxy-propyl)-2-nitro-imidazole [18F]-fluoromisonidazole
Description: Brain scan with radiopharmaceutical imaging tracer that directly assesses tumor hypoxia
Study NCT01246869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [15O]water
Description: Brain scan with imaging tracer used for measuring tumor blood flow/perfusion
Study NCT01246869 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Brain scan to assess tumor size and tumor blood flow/perfusion
Study NCT03494400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training Presential
Description: The intervention will last 24 weeks, in which the presential training group will undergo aerobic training three times a week on interspersed days, more follow-up.
Study NCT03494400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training Presential
Description: The intervention will last 24 weeks, in which the presential training group will undergo aerobic training three times a week on interspersed days, more follow-up.
Study NCT03494400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training Home-based
Description: The intervention will last 24 weeks, the group accompanied by the distance will carry out the activities in their preferred place under the distance supervision of professionals and every 14 days must attend the UNESP to adjust the intensity and verification of attendance to the proposed activities, more follow-up.
Study NCT03494400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training Home-based
Description: The intervention will last 24 weeks, the group accompanied by the distance will carry out the activities in their preferred place under the distance supervision of professionals and every 14 days must attend the UNESP to adjust the intensity and verification of attendance to the proposed activities, more follow-up.
Study NCT03843632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VARIVAX™
Description: VARIVAX™ administered by SC injection as 0.5 mL Varicella Virus Vaccine Live in sterile suspension on Day 1 (all participants) and Day 43 (adult and adolescent participants).
Study NCT02464475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative treatment
Study NCT02464475 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham osteopathic treatment
Study NCT03320798 — intervention group
Intervention type: OTHER
Intervention: Data record
Study NCT00784433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alcohol
Description: 150 cc
Study NCT00784433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: alcohol
Description: 150 cc
Study NCT00542048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG®-1
Description: EndoTAG®-1 22 mg/m² twice weekly
Study NCT01119768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment
Study NCT01119768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up
Study NCT02696122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Group
Description: General anesthesia willl be induced with propofol 2 mg mg. kg-1 and alfentanyl 30 mcg.kg-1. Once an appropriate depth of anesthesia had been obtained, a laryngeal mask airway (LMA) will be positioned. The anesthesia will be maintained by propofol 4 to 5 mg. kg-1.h-1. Ventilation will controlled by adjusting the flow volume and respiratory rate to keep the end-tidal CO2 level (PETCO2) between 30 and 40 mmHg. For local anesthesia, approximately 50 ml of 0.5% ropivacaive will infiltrated along the line of incision in the subcutaneous plane, followed by peripheral nerve block technique (e.g., ilioinguinal-hypogastric nerve block) and local wound infiltration at the fascial level.
Study NCT02696122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Spinal puncture will be performed with the patient in the sitting position, using 27G disposable Quincke needles (B. Braun, Meisungen, AG). After obtaining CSF, 15 mg of 0.5% hyperbaric bupivacaine will be injected.
Study NCT03020563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: Liposomal Bupivacaine
Study NCT03020563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine
Study NCT03395808 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tramadol
Description: IV; 50 mg given at Hours 0, 2, 4, 8 and every 4 hours thereafter, for a total of up to 43 doses
Study NCT03781830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
Study NCT04707404 — intervention group
Intervention type: PROCEDURE
Intervention: Cranioplasty
Description: The surgery implanted artificial material to repair the skull defect.
Study NCT04837872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Physical Therapy (MPT)
Description: Individualized physical therapy and static progressive splint (flexion with or without extension splint).
Study NCT02634840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral sagittal split osteotomy
Description: surgical technique to split the mandibular ramus through three osteotomy lines on the medial-cranial, buccal-caudal and anterior surface to facilitate a split of the posterior border of the mandible without injury of the inferior alveolar nerve
Study NCT01179360 — intervention group
Intervention type: OTHER
Intervention: Integrated FDG PET/CT
Description: Optimized PET/CT imaging with dedicated head-and-neck protocol
Study NCT03620422 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mannitol
Description: Mannitol-Induced Cough Challenge
Study NCT03620422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: Mannitol-Induced Cough Challenge
Study NCT03620422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: Mannitol-Induced Cough Challenge
Study NCT03620422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol 5mg/mL
Description: Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge
Study NCT03620422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inhl 3Ml
Description: Nebulized 0.9% saline given prior to Mannitol-Induced Cough Challenge
Study NCT00525135 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Valproic Acid
Description: OUTLINE: This is a pilot study.~Patients receive valproic acid daily for 16 weeks. Dose increases on Days 4 and 8; dose remains the same for weeks 2-10. All patients will undergo a Thyrogen® (thyrotropin alfa for injection) RAI scan at entry to the study and after completion of 10 weeks of valproic acid treatment.~Quality of life is assessed at the end of every week through a study diary.~Patients are followed at 1, 2, 4, 6, 8, 10, 12, 14, 16, and 17 (Schedule 1) weeks. Patients return for follow-up at 3, 6, and 12 months.
Study NCT03327584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrocentesis
Description: Athrocentesis
Study NCT04100122 — intervention group
Intervention type: PROCEDURE
Intervention: Blood drawing
Description: Blood drawn will be done once using 15 mL of blood volume (Serum or plasma samples will be collected during the routine follow up of level of sIgE to wheat or during the oral food challenge test which intravenous insertion routinely prepared in case of the emergency reaction occurred). The specimen will be transferred to the Icahn School of Medicine at Mount Sinai, New York, USA for Laboratory processing (Luminex-based peptide assay)
Study NCT02002884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (8 Units per kg body weight)
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
Study NCT02002884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (6 Units per kg body weight)
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
Study NCT02002884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (2 Units per kg body weight)
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
Study NCT00462670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OPC-41061(Tolvaptan)
Description: 0, 15mg of OPC-41061 per day for 7days p.o. administration
Study NCT00462670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061(Tolvaptan)
Description: 0, 15mg of OPC-41061 per day for 7days p.o. administration
Study NCT03498222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Administered at a fixed dose of 1200 mg (equivalent to an average body weight-based dose of 15mg/kg) by intravenous (IV) infusion every 3 weeks (21 days).
Study NCT03498222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered at a fixed dose of 500mg/m2 by IV infusion every 3 weeks.
Study NCT03498222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered at a fixed dose of AUC5 by IV infusion every 3 weeks.
Study NCT03498222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG20
Description: Administered by intramuscular (IM) injection to patients once weekly.
Study NCT03933111 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: local sound velocity measurement
Description: All patients are scanned by Fuji film su-9000 ultrasonic system. After the lesions are found, local sound velocity measurement technology will be used to measure the sound velocity in the lesions.Pathology diagnosis or clinical follow-up results will be regard as diagnostic gold standard divide the patients into pancreatic cancer and pancreatic cancer group.
Study NCT04461795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]
Description: 225 MG/1.5 ML Subcutaneous Solution
Study NCT01681108 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle counseling
Description: Individualized meal planning and exercise regimen sessions will be developed for each participant
Study NCT01226563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IK-5001
Description: 4 mL (+/- 0.2 mL) administered through intracoronary slow bolus injection over 15 to 30 seconds at least 2 days after PCI but within 5 days of onset of symptoms.